MYO Stock Analysis: Buy, Sell, or Hold?
MYO - Myomo Inc.
$1.10
-0.06 (-5.17%)
▼
5d:
+6.8%
30d:
-16.03%
90d:
+57.14%
BUY
HIGH Confidence
Analysis Updated: Jul 10, 2026 12:00 AM ET
Earnings: Aug 10, 2026
27d
Get Alerted When MYO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: MYO shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
✅ BUY SIGNAL: MYO shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
In-depth Analysis How we analyze
Valuation Analysis: MYO is currently trading at $1.10, which is considered slightly low relative to its 30-day fair value range of $1.07 to $1.36.
Technical Outlook: Technically, MYO is in a strong downtrend. Immediate support is located at $0.96, while resistance sits at $1.48. Short-term momentum is weak, with the stock down 5.2% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $4.42 (+301.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, MYO is in a strong downtrend. Immediate support is located at $0.96, while resistance sits at $1.48. Short-term momentum is weak, with the stock down 5.2% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $4.42 (+301.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$1.07 -
$1.36
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.2%)
- BULLISH: Trading 301.8% below Wall St target ($4.42)
Trading Range Analysis
30-Day Trading Range
$1.07 -
$1.36
Current vs Trading Range
SLIGHTLY LOW
Expected Move (7 Days)
±$0.15
(13.7%)
Support & Resistance Levels
Support Level
$0.96
Resistance Level
$1.48
Current Trend
Strong Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.34
Wall Street Target
$4.42
(+301.8%)
Revenue Growth (YoY)
2.9%
Profit Margin
-36.7%
Share & Embed Analysis
Last updated: July 13, 2026 4:03 AM ET
Data refreshes hourly during market hours. Next update: 5:03 AM
Data refreshes hourly during market hours. Next update: 5:03 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MYO showing a specific setup today?
Insider Activity (6 Months)
3
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Heather C Getz
BUY
20000 shares
2026-03-16
Thomas F Kirk
BUY
72000 shares
2026-03-13
Heather C Getz
BUY
70000 shares
2026-03-12
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$74 | 65 BUY |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$85 | 58 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$386 | 63 BUY |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$116 | 63 BUY |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$239 | 58 HOLD |
